Nanjing Vazyme BiotechLtd Future Growth
Future criteria checks 5/6
Nanjing Vazyme BiotechLtd is forecast to grow earnings and revenue by 100.6% and 25.4% per annum respectively while EPS is expected to grow by 101% per annum.
Key information
100.6%
Earnings growth rate
101.0%
EPS growth rate
| Biotechs earnings growth | 33.9% |
| Revenue growth rate | 25.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Feb 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 2,011 | 467 | N/A | 536 | 3 |
| 12/31/2024 | 1,600 | 319 | N/A | 285 | 3 |
| 3/31/2024 | 1,285 | -15 | 12 | 181 | N/A |
| 12/31/2023 | 1,286 | -71 | -80 | 153 | N/A |
| 9/30/2023 | 2,133 | -232 | 152 | 589 | N/A |
| 6/30/2023 | 2,520 | -101 | 126 | 649 | N/A |
| 3/31/2023 | 2,896 | 112 | -128 | 553 | N/A |
| 12/31/2022 | 3,569 | 594 | -228 | 735 | N/A |
| 9/30/2022 | 2,885 | 878 | -367 | 445 | N/A |
| 6/30/2022 | 2,663 | 900 | -291 | 440 | N/A |
| 3/31/2022 | 2,302 | 773 | -123 | 453 | N/A |
| 12/31/2021 | 1,869 | 678 | 355 | 617 | N/A |
| 9/30/2021 | 1,715 | 767 | 315 | 583 | N/A |
| 12/31/2020 | 1,564 | 822 | 651 | 804 | N/A |
| 12/31/2019 | 268 | 26 | -5 | 15 | N/A |
| 12/31/2018 | 171 | 1 | -36 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688105 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 688105 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688105 is expected to become profitable in the next 3 years.
Revenue vs Market: 688105's revenue (25.4% per year) is forecast to grow faster than the CN market (14.5% per year).
High Growth Revenue: 688105's revenue (25.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 688105's Return on Equity is forecast to be high in 3 years time